HIV + AIDS Med Card

zidovudine class

nucleoside reverse transcriptase inhibitor (NRTI)

zidovudine moa

blocks addition of further nucleosides and terminates viral replication

zidovudine admin

PO

IV

zidovudine use

combo therapy for HIV

monotherapy for pregnant patients to stop transmission during labor

zidovudine ae

BBW - blood dyscrasias (any abnormal blood levels)

lactic acidosis

severe hepatomegaly

zidovudine considerations

give around the clock to maintain serum concentrations

monitor labs closely

efavirenz class

nonnucleoside reverse transcriptase inhibitor (NNRTI)

efavirenz moa

binds to reverse transcriptase and blocks HIV replication

efavirenz use

HIV combo therapy

efavirenz ae

CNS depression

hematuria

depression

SJS

TEN

efavirenz contraindications

suicidal ideation

pregnancy or breastfeeding

efavirenz considerations

avoid high fat meals around dosing (increases absorption)

saquinavir mesylate class

protease inhibitor

saquinavir mesylate moa

inhibits HIV protease

prevents cleavage of polyproteins

saquinavir mesylate use

HIV combo therapy

saquinavir mesylate ae

chest pain

suicidal ideation

prolonged QT

blood dyscrasias

saquinavir mesylate contraindications

prolonged QT

hepatic impairment

hypokalemia

hypomagnesemia

saquinavir mesylate considerations

obtain EKG prior to intiation + 3-4 days after start

check electrolytes

raltegravir class

integrase strand transfer inhibitor

raltegravir moa

blocks HIV 1 integrase

prevents formation of provirus

raltegravir admin

PO

raltegravir use

combo therapy

raltegravir ae

rhabo

GI effects

raltegravir considerations

monitor for muscle symptoms

enfurvirtide class

fusion protein inhibitor

enfurvirtide moa

inhibits HIV from binding, fusing, entering human cells

enfurvirtide admin

SubQ (connective tissue)

enfurvirtide use

treatment experienced patients

combo therapy

enfurvirtide ae

GI upset

injection site reaction

fatigue

insomnia

enfurvirtide considerations

rotate injection sites (arm, abdomen, thigh)

maraviroc class

CCR5 antagonist

maraviroc moa

blocks receptor site

prevents HIV entry and replication

maraviroc admin

PO

maraviroc use

combo therapy for detectable CCR5 tropic HIV with viral replication

maraviroc ae

BBW - hepatotoxicity

fever

rash

CNS depression

maraviroc contraindications

renal impairment

potent CYP3A4 inhibitor medication use

cobicistat class

cytochrome P450 inhibitor

cobicistat moa

inhibits CYP3A metabolism

increases systemic exposure of CYP3A substrates

cobicistat admin

PO

cobicistat use

boosting agent to increase antiretroviral activity

cobicistat considerations

when used with other drugs alters their drug level (decrease other drug levels when giving)

Biktarvy moa

inhibits HIV integrase

blocks viral DNA integration

Biktarvy admin

PO (once daily)

Biktarvy use

complete HIV regiment (no additional ARVs needed)

Biktarvy ae

BBW - severe acute HBV exacerbation in coinfected patients

Biktarvy considerations

monitor hepatic function

do not stop abruptly

Cabenuva moa

inhibits viral replication

Cabenuva admin

IM (once monthly) (ventrogluteal only)

Cabenuva use

maintenance therapy

Cabenuva ae

injection site reaction

pain

fever

Cabenuva considerations

monitor hepatic function

oral trial required before injections

Truvada moa

prevents HIV replication if exposure occurs (PrEP)

Truvada admin

PO (once daily)

Truvada use

patients not infected but high risk

Truvada ae

decreased bone density (osteopneia)

renal effects

Truvada considerations

check renal function

take continuously

does not prevent STI or pregnancy

Descovy moa

blocks HIV reverse transcriptase (PrEP)

Descovy admin

PO

Descovy considerations

safe to use with osteporosis + kidney disease

used for HIV prevention